Minerva Capital Research Solutions

SMS Pharmaceuticals

NSE: SMSPHARMABSE: 532815
Compare with peers
₹ 477.00▲ 34.2 (+7.72%)28 Oct, 03:29 pm IST
Market cap
₹ 3,876 Cr.
P/E
43.6x
P/B
5.11x
52-week range
270.1 – 494.45
ROE
14%
ROCE
13%
Dividend yield
0.1%
Debt / equity
0.46
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 221 companies →

SMS Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)43.6 against a typical 34.3: pricier than most peers (1st = cheapest).140th of 220
  • Sales growth+5.6% against a typical +15.6% from a year earlier.132nd of 197
  • Profit growth+5% against a typical +18.9% from a year earlier.100th of 160
  • Share price, 3 months+20.3% against a typical −0.5%.34th of 200
  • Size₹ 3,876.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).60th of 199

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

Adequate safety

Rated A by CARE
A
DefaultRiskyModerateSafeVery safe
  • No warnings from the agency.
AgencyCurrent ratingOutlookAs of
CARECARE AStable9 Sep 2026
Credit rating actions
RatingDetails
9 Sep 2026
▼ Outlook cut
CARE A
Outlook Positive → Stable
—CARE₹ 622.9 Cr.
4 Dec 2025
▲ Upgrade
CARE A—CARE₹ 403.7 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
1 Aug 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
31 Jul 2026Financial Results/Other business mattersSMSPHARMA : 31-Jul-2026 : The Company has informed the Exchange that a Board meeting to be held on August 01, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on July 31, 2026, To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
22 May 2026Financial Results/Dividend/Other business mattersTo consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
7 Feb 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended December 31, 2025 and other business matters
8 Nov 2025Financial Results/Other business mattersTo consider and approve the financial results for the period ended September 30, 2025 and other business matters
9 Aug 2025Financial Results/Other business mattersTo consider and approve the financial results for the period ended Jun 30, 2025 and other business matters

Share price

1Y change +59.16%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales167161246164197173248196242210238207
Expenses139132212131165140207157194167198166
Operating Profit282934343133413948444041
OPM %17%18%14%20%16%19%16%20%20%21%17%20%
Other Income112112111432
Interest666554566656
Depreciation88889991010101010
Profit before tax151722222022292434312727
Tax %21%26%26%25%29%24%30%23%26%26%23%26%
Net Profit121117161418202025233321
EPS in Rs1.381.362.041.951.662.152.292.312.72.513.492.23

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
4%
5 Years
10%
3 Years
19%
TTM
10%
Compounded Profit Growth
10 Years
10%
5 Years
10%
3 Years
155%
TTM
40%
Stock Price CAGR
10 Years
16%
5 Years
16%
3 Years
42%
TTM
—
Return on Equity
10 Years
11%
5 Years
10%
3 Years
12%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
68.07%
+1.8 pts in a year
FIIs
0.65%
+0.62 pts in a year
DIIs
2.83%
−0.2 pts in a year
Public
28.45%
−2.23 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 43.6xEPS (12 months) ₹ 10.93Median P/E 14.7x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
SMS Pharmaceuticals₹ 477.00₹ 3,876 Cr.43.6x5.1x14%—
Sun Pharmaceutical Industries₹ 1,743.00₹ 4,18,194 Cr.38.4x5.6x14.2%19.1%
Divi's Laboratories₹ 8,984.00₹ 2,38,497 Cr.73.3x11.5x16.2%24.3%
Torrent Pharmaceuticals₹ 4,482.00₹ 1,70,475 Cr.72.7x19.2x27.1%15.3%
Cipla₹ 1,337.00₹ 1,08,011 Cr.27.6x3.3x11.8%13.7%
Zydus Lifesciences₹ 1,127.85₹ 1,12,503 Cr.21.2x4.2x19.7%18.5%

Management

Ramesh Babu Potluri
Executive Chairman of the Board, Managing Director
Lakshmi Narayana Tammineedi
Chief Financial Officer
Thirumalesh Tumma
Chief Compliance Officer, Company Secretary
Vamsi Krishna Potluri
Whole Time Director

Prices are delayed and for information only. Nothing on this page is investment advice.